Report from Incubate Policy Lab and Charles River Associates Finds Price Controls Would Decrease Investment in Critical Therapeutic Areas

Washington, D.C., Nov. 18, 2021 (GLOBE NEWSWIRE) — Today, Incubate Policy Lab and Charles River Associates published a report detailing how investment into therapies for rare diseases and oncology will plummet if Congress enacts price controls. “Despite pleas from the life-science investment community, Congress is moving forward with government-mandated prices for medicines,” said John Stanford, Incubate’s executive director.

Read the source article at Stock Market Quotes and News
2021-11-18 22:09:03